Psoriasis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
This trial has three groups. A person may be considered for one of the following:
Group 1 – People who took deucravacitinib (a psoriasis medication) during pregnancy:
- People who are currently pregnant at the time of enrolment
- People who have been diagnosed with psoriasis, confirmed by medical records where possible
- People who took deucravacitinib at any dose, for any length of time, starting from 2 days before conception through to the end of the pregnancy
- People who agree to all study requirements, including scheduled interviews, sharing of medical records, and a physical examination of any live-born baby to check for birth differences
Group 2 – People with psoriasis who did not take deucravacitinib during pregnancy:
- People who are currently pregnant at the time of enrolment
- People who have been diagnosed with psoriasis, confirmed by medical records where possible
- People who may be taking other systemic (whole-body) treatments for psoriasis
- People who agree to all study requirements, including scheduled interviews, sharing of medical records, and a physical examination of any live-born baby to check for birth differences
Group 3 – People without psoriasis who did not take deucravacitinib during pregnancy:
- People who are currently pregnant at the time of enrolment
- People who agree to all study requirements, including scheduled interviews, sharing of medical records, and a physical examination of any live-born baby to check for birth differences
Who may not be able to join:
The following apply to all three groups unless otherwise noted:
- People who have previously enrolled in this same study during an earlier pregnancy
- People whose pregnancy had already ended before enrolment — enrolment must happen while the pregnancy is still ongoing
- People who had a medical test before enrolment that confirmed a major birth difference in the baby (note: having had a normal or inconclusive screening test before enrolment does not automatically prevent participation — confirm with trial site)
Additional restrictions for Group 1:
- People who took deucravacitinib for a condition other than psoriasis
- People who did not actually take deucravacitinib within the required time window (from 2 days before conception to the end of the pregnancy)
- People who took certain other medications called oral TYK2 inhibitors or oral JAK inhibitors during a specific window around the time of conception through to the end of pregnancy (confirm with trial site)
- People who took methotrexate or an oral retinoid (a vitamin A-related medication) at any point
Additional restrictions for Group 2:
- People who took deucravacitinib, other oral TYK2 inhibitors, or oral JAK inhibitors during a specific window around the time of conception through to the end of pregnancy (confirm with trial site)
- People who took methotrexate or an oral retinoid
Additional restrictions for Group 3:
- People who took deucravacitinib, oral TYK2 inhibitors, or oral JAK inhibitors during a specific window around the time of conception through to the end of pregnancy (confirm with trial site)
- People who were exposed during pregnancy to any substance that is known, suspected, or considered possible to cause birth differences in humans, as determined by the OTIS Research Center (confirm with trial site for the full list)
- People who have been diagnosed with psoriasis or any other autoimmune disease
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of major congenital malformations among infants
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.